U.S. market Closed. Opens in 4 hours 53 minutes

MBRX | Moleculin Biotech, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.6100 - 2.8400
52 Week Range 0.4000 - 6.24
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 33,278
Average Volume 40,533
Shares Outstanding 3,001,900
Market Cap 8,015,073
Sector Healthcare
Industry Biotechnology
IPO Date 2016-06-02
Valuation
Profitability
Growth
Health
P/E Ratio -0.22
Forward P/E Ratio N/A
EPS -12.04
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 18
Country USA
Website MBRX
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
*Chart delayed
Analyzing fundamentals for MBRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see MBRX Fundamentals page.

Watching at MBRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on MBRX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙